for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sensus Healthcare Inc

SRTS.OQ

Latest Trade

6.21USD

Change

-0.04(-0.64%)

Volume

284

Today's Range

6.21

 - 

6.28

52 Week Range

4.75

 - 

9.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.25
Open
6.28
Volume
284
3M AVG Volume
0.32
Today's High
6.28
Today's Low
6.21
52 Week High
9.23
52 Week Low
4.75
Shares Out (MIL)
16.50
Market Cap (MIL)
103.11
Forward P/E
-64.37
Dividend (Yield %)
--

Latest Developments

More

Sensus Healthcare Says Q2 Earnings Per Share $0.01

Sensus Healthcare Says On June 4 Entered Into Amendment No. 1 To Warrant Agreement With American Stock Transfer & Trust Company

Sensus Healthcare Reports Q4 EPS $0.01

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sensus Healthcare Inc

Sensus Healthcare, Inc., formerly Sensus Healthcare, LLC, is a manufacturer of superficial radiation therapy devices. The Company designs, manufactures and markets medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy. The superficial radiation therapy is an alternative to surgical basal cell carcinoma treatment and squamous cell carcinoma treatment. The Company's product, the SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions, such as keloids. The SRT-100 treats primary lesions that would otherwise be difficult or require surgery involving sensitive areas of the head and neck regions, such as the fold in the nose, eyelids, lips, corner of the mouth and the lining of the ear.

Industry

Medical Equipment & Supplies

Contact Info

851 Broken Sound Pkwy NW Ste 215

+1.561.9225808

https://sensushealthcare.com/

Executive Leadership

Joseph C. Sardano

Chairman of the Board, Chief Executive Officer

Kalman Fishman

Co-Founder, Chief Operating Officer, Chief Technology Officer

Richard Golin

Co-Founder, Executive Vice President - Sales, Oncology and International

Arthur R. Levine

Chief Financial Officer

Stephen Brad Cohen

Senior Vice President - Strategic Initiatives and Dermatology

Key Stats

2.43 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.030

2017

-0.280

2018

-0.140

2019(E)

-0.097
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.77
Price To Book (MRQ)
3.77
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-11.60
Return on Equity (TTM)
-8.45

Latest News

BRIEF-Sensus Healthcare Reports Q1 Loss Per Share Of $0.08

* SENSUS HEALTHCARE REPORTS FIRST QUARTER FINANCIAL RESULTS FEATURING 37 PCT REVENUE GROWTH

BRIEF-Sensus Healthcare Expands International Business To Meet Rising Patient Demand For Non-Invasive Skin Cancer And Keloid Treatments

* SENSUS HEALTHCARE EXPANDS INTERNATIONAL BUSINESS TO MEET RISING PATIENT DEMAND FOR NON-INVASIVE SKIN CANCER AND KELOID TREATMENTS

BRIEF-Sensus Healthcare Collaborates With Birchbiomed To Treat And Prevent Scarring For Keloids Patients

* SENSUS HEALTHCARE LAUNCHES COLLABORATION WITH BIRCHBIOMED TO TREAT AND PREVENT SCARRING FOR KELOIDS PATIENTS AROUND THE WORLD Source text for Eikon: Further company coverage:

BRIEF-Sensus Healthcare Reports Q4 Loss Per Share $0.03

* SENSUS HEALTHCARE REPORTS RECORD REVENUE FOR 2017 FOURTH QUARTER AND FULL YEAR

BRIEF-Sensus Healthcare files for mixed shelf of up to $20 mln - SEC filing

* Sensus Healthcare Inc files for mixed shelf of up to $20 million - SEC filing Source text: (http://bit.ly/2j7hKwL) Further company coverage:

BRIEF-Sensus Healthcare reports Q3 loss per share of $0.07

* Sensus Healthcare reports third quarter financial results featuring revenue up 44 percent

BRIEF-Sensus Healthcare launches SRT-100 in China for Keloid treatment

* Sensus Healthcare Inc - has launched SRT-100 in China for treatment and prevention of Keloids with Chindex Medical Limited

BRIEF-Sensus Healthcare says SRT-100 now cleared for sale in Mexico​

* Sensus Healthcare Inc - announces that SRT-100 is now cleared for sale in Mexico

BRIEF-Stratpharma AG & Sensus Healthcare announce strategic collaboration

* Stratpharma AG & Sensus Healthcare announce strategic collaboration for transformative superficial radiation therapy & post-treatment care Source text for Eikon: Further company coverage:

BRIEF-Sensus Healthcare Q2 loss per share $0.06

* Sensus Healthcare reports record second quarter financial results

BRIEF-Sensus Healthcare Q1 revenue rose 43.5 percent to $4.4 million

* Sensus Healthcare Inc - Cash, cash equivalents and investments were $11.0 million as of March 31, 2017.

BRIEF-Sensus Healthcare reports Q4 results

* Sensus Healthcare Inc - sold 19 systems in q4 and a total of 59 systems in 2016, increasing worldwide installed base to 271 units as of Dec 31, 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up